Entera Bio (ENTX) Debt Ratio (2017 - 2026)
Entera Bio (ENTX) recorded quarterly Debt Ratio of 0.04 in Q1 2026, up 75.75% on a QoQ basis from 0.02 in Q4 2025, and up 81.13% year-over-year from 0.02 in Q1 2025.
Entera Bio (ENTX) Debt Ratio (2017 - 2026) Analysis & Trends
Entera Bio has disclosed Debt Ratio across 3 years of filings, most recently posting 0.04 for Q1 2026.
- Quarterly Debt Ratio rose 81.13% year-over-year to 0.04 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.04 (up 81.13% YoY) and the FY2025 annual result came in at 0.02, changed N/A from the prior year.
- Debt Ratio improved to 0.04 in Q1 2026, from 0.02 in the prior quarter.
- Over five years, Debt Ratio peaked at 0.04 in Q1 2026 and troughed at 0.02 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 0.18 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | - |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Entera Bio | 57.79 Mn | 53.65 Mn | - | 0.04 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.04 |
| Dec 31, 2025 | 0.02 |
| Sep 30, 2025 | 0.03 |
| Jun 30, 2025 | 0.03 |
| Mar 31, 2025 | 0.02 |
| Dec 31, 2017 | 0.29 |